A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose and an Open-Label Fixed-Dose Study in Patients With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RGLS8429
Latest Information Update: 08 May 2025
At a glance
- Drugs Farabursen (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Regulus Therapeutics
Most Recent Events
- 30 Apr 2025 Status changed from active, no longer recruiting to completed.
- 27 Mar 2025 According to a Regulus Therapeutics media release, company announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the treatment of ADPKD.
- 27 Mar 2025 Results published in the Regulus Therapeutics media release